Improving the prediction of acute myeloid leukaemia outcomes by complementing mutational profiling with ex vivo chemosensitivity

Correction to: A phase I–II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia

(2018) David Martínez-Cuadrón et al.   ANNALS OF HEMATOLOGY

Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study

(2018) Ronan T. Swords et al.   LEUKEMIA RESEARCH

Novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia

(2018) Esther Onecha et al.   HAEMATOLOGICA

A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients

(2018) David Martínez-Cuadrón et al.   LEUKEMIA RESEARCH

Functional genomic landscape of acute myeloid leukaemia

(2018) Jeffrey W. Tyner et al.   NATURE

COSMIC: the Catalogue Of Somatic Mutations In Cancer

(2018) John G Tate et al.   NUCLEIC ACIDS RESEARCH

The target landscape of clinical kinase drugs

(2017) Susan Klaeger et al.   SCIENCE

Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes

(2017) M. Teresa Cedena et al.   Oncotarget

Precision and recall oncology: combining multiple gene mutations for improved identification of drug-sensitive tumours

(2017) Stefan Naulaerts et al.   Oncotarget

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

(2016) Hartmut Döhner et al.   BLOOD

Genomic Classification and Prognosis in Acute Myeloid Leukemia

(2016) Elli Papaemmanuil et al.   NEW ENGLAND JOURNAL OF MEDICINE

Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center

(2014) R B Walter et al.   LEUKEMIA

Pharmacological Profiles of Acute Myeloid Leukemia Treatments in Patient Samples by Automated Flow Cytometry: A Bridge to Individualized Medicine

(2013) Teresa A. Bennett et al.   Clinical Lymphoma Myeloma & Leukemia

Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia

(2013) T. Pemovska et al.   Cancer Discovery

EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols

(2012) T Kalina et al.   LEUKEMIA

EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes

(2012) J J M van Dongen et al.   LEUKEMIA

Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia

(2012) Jay P. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo

(2011) T. Sato et al.   BLOOD

Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias

(2011) R Itzykson et al.   LEUKEMIA

How I treat acute myeloid leukemia

(2010) J. M. Rowe et al.   BLOOD